Welcome to the e-CCO Library!

P389: The value of oxidative stress parameters to predict histological severity in ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

B. Canbakan*1, K. Atay1, E. Koroglu1, M. Tuncer1, H. Senturk2

Created: Friday, 22 February 2019, 9:49 AM
P390 New features of molecular diagnostics of the regulation of molecular apoptotic pathway in ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A.A. Iakovlev, A. Volkov, I. Shcherbakova, G. Tarasova, S. Malakhanov, O. Bashtovaya

Created: Thursday, 30 January 2020, 10:12 AM
P390: Diverting Loop Ileostomy in Medically Refractory Crohn's Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Patel, P.(1);Wu, L.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P390: Efficacy and safety of mesenchymal stem cell therapy with darvadstrocel for complex perianal fistulizing Crohn´s disease: multicentric experience in the Basque Country and Navarre
Year: 2022
Source: ECCO'22
Authors: Elorza, A.(1);Arzallus, T.(2);Izagirre, A.(2);Vicuña, M.(3);Rodriguez, C.(3);Cabriada, J.L.(1);Rodriguez-Lago, I.(1);
Created: Friday, 11 February 2022, 3:52 PM
P390: Methotrexate is not superior to placebo in maintaining remission in patients with ulcerative colitis: results from the MERIT-UC study
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Herfarth1*, E.L. Barnes1, S. Jackson1, J.F. Valentine2, J. Hanson3, P.D.R. Higgins4, K.L. Isaacs1, M.T. Osterman5, B.E. Sands6, J.D. Lewis5, MERIT-UC study group

Created: Thursday, 21 February 2019, 9:14 AM
P390: Open-label study to evaluate the pharmacokinetics of fidaxomicin in inflammatory bowel disease patients with Clostridium difficile infection (the PROFILE study): pharmacokinetics analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Högenauer C.1, Mahida Y.2, Stallmach A.3, Marteau P.4, Rydzewska G.5, Ivashkin V.6, Gargalianos-Kakolyris P.7, Michon I.8, Adomakoh N.9, Reinisch W.*10

Created: Wednesday, 20 February 2019, 10:36 AM
P390: The impact of anti-TNF therapy in adjuvant setting on postoperative recurrence patterns over decades in complicated Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

F. Colombo*1, A. Frontali2, L. Conti1, C. Baldi1, S. Ardizzone3, G. Maconi3, F. Corsi4, D. Foschi1, G. M. Sampietro1

Created: Friday, 22 February 2019, 9:41 AM
P390: To double dose or not to double dose? That is the question: Single centre experience in the use of infliximab antibodies and levels in a paediatric IBD (pIBD) cohort
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

B. Huggett*, S. Sider, S. Chadokufa, N. Acton, N. Shah, F. Kiparissi

Created: Friday, 22 February 2019, 9:49 AM
P390: Ustekinumab modulates IL-12 and IL-23-related cell type-specific inflammatory transcriptional states in Ulcerative Colitis induction therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Richards, D.(1)*;Venkat, S.(1);Freeman, T.C.(1);Mcrae, B.(1);Hoops, T.(1);Marano, C.(1);Branigan, P.(1);
Created: Friday, 14 July 2023, 11:05 AM
P391 Side-to-side strictureplasty and its modification over the ileocecal valve for extensive Crohn’s ileitis: single-centre long-term outcome
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Bislenghi1, M. Ferrante2, J.P.G. Sabino2, B. Verstockt2, B. Martin Perez1, A. Wolthuis1, S. Vermeire2, A. D’hoore1

Created: Thursday, 30 January 2020, 10:12 AM
P391: Antibiotics in pediatric Inflammatory Bowel Diseases: a systematic review
Year: 2021
Source: ECCO'21 Virtual
Authors: Verburgt, C.(1,2);Heutink, W.P.(3);Kuilboer, L.I.M.(1);Dickmann, J.D.(1);van Etten-Jamaludin, F.S.(4);Benninga, M.A.(1);de Jonge, W.J.(2,5);Van Limbergen, J.E.(1,2,6);Tabbers, M.M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P391: Are cut-off ranges of Infliximab serum levels in Crohn’s disease always the same in clinical practice?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Valdes Delgado1, M. Guerra Veloz*1, M. Belvis Jimenez1, B. Maldonado Pérez1, L. Castro Laria1, A. Benítez Roldán1, R. Perea Amarillo1, V. Merino Bohorquez2, M. A. Calleja Hernandez2, T. Ortiz3, A. Caunedo Álvarez1, A. Vilches Arenas4, A. Saez Diaz5, F. Argüelles-Arias1

Created: Friday, 22 February 2019, 9:41 AM
P391: Differential use of vedolizumab in ulcerative colitis and Crohn's disease. Real life results from 2 tertiary referral centres in the United Kingdom
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kamperidis N.*1, Cavazza A.2, Wahed M.2, Arebi N.1

Created: Wednesday, 20 February 2019, 10:36 AM
P391: Gender differences in adalimumab continuation rates: Results of a Crohn’s disease cohort
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Lie*, J. Kreijne, J. van der Woude

Created: Friday, 22 February 2019, 9:49 AM
P391: The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn’s disease but not in ulcerative colitis. A nationwide study from the Eneida registry
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Guasch1, A. Clos2, I. Ordás3,4, V. García-Sánchez5, J.P. Gisbert4,6, C. Taxonera7, I. Vera8, M. Mínguez9, J. Guardiola10, A. López-Sanromán11, M. Rivero-Tirado12, P. Nos13, F. Gomollón4,14, A.Y. Carbajo15, R. de Francisco16, M.D. Martín-Arranz17, E. Garcia-Planella18, S. García-López19, L. de Castro20, X. Calvet4,21, R. Camargo22, M. Esteve4,23, B. Sicilia24, M. Andreu25, A. Macho26, M. Piqueras27, F. Bermejo28, A. Gutiérrez29, D. Busquets30, P. Martínez-Montiel31, J. Hinojosa32, J.L. Pérez-Calle33, L. Bujanda34, A. Rodríguez-Pérez35, R. Lorente36, N. Jiménez37, M. Navarro-Llavat38, J.L. Cabriada39, P. Camo40, M. Van Domselaar41, E. Rodríguez-González42, C. Rodríguez-Gutiérrez43, J.M. Huguet44, A.J. Lucendo45, F. Argüelles46, P. Almela47, O. Merino48, M. Calafat49, M. Ogueta50, M. Charro51, J. Llaó52, C. Muñoz53, L. Ramos54, Á. Abad55, Ó. Roncero56, M. Barreiro-de-Acosta57, E. Sesé58, M. Mañosa2,4, E. Domènech2,4*

Created: Thursday, 21 February 2019, 9:14 AM
P391: Unpacking the different popular diets for pediatric Crohn's disease - concerns around nutritional adequacy
Year: 2022
Source: ECCO'22
Authors: Carmody , E.(1);Haskett , J.(1);Parkinson-McGraw , L.(1);Grover , Z.(1);Martinez , A.(1);Rashid , M.(1);Otley MD MSc FRCPC, A.(1);
Created: Friday, 11 February 2022, 3:52 PM
P392: A mobile application to monitor Inflammatory Bowel Disease patients during intravenous biologic treatment: Results of a feasibility study
Year: 2021
Source: ECCO'21 Virtual
Authors: Van Erp, L.W.(1);Groenen, M.J.M.(1);Heida, W.(1);Wisse, J.(1);Roosenboom, B.(1);Wahab, P.J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P392: Body mass index has no effect on treatment response in Crohn's disease patients with moderate disease activity who receive adalimumab
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Soufleris*1, K. Fasoulas1, N. Kafalis1, G. Lazaraki1, D. Tzilves1

Created: Friday, 22 February 2019, 9:41 AM